Insulet (NASDAQ:PODD) Hits New 1-Year Low – What’s Next?

Insulet Corporation (NASDAQ:PODD) reached a new 52-week low on Monday . The company traded as low as $139.23 and last traded at $139.9680, with a volume of 159812 shares. The stock had previously closed at $145.76.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of analyst reports. Robert W. Baird dropped their price objective on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Piper Sandler dropped their price target on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Finally, Evercore lowered their target price on Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $240.78.

Insulet Stock Down 4.1%

The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of 32.53, a P/E/G ratio of 1.15 and a beta of 1.13. The stock has a 50 day moving average of $164.18 and a 200 day moving average of $225.67. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Larson Financial Group LLC lifted its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the fourth quarter valued at approximately $26,000. DV Equities LLC bought a new position in shares of Insulet during the fourth quarter valued at approximately $28,000. Elyxium Wealth LLC bought a new position in shares of Insulet during the fourth quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.